中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

黄连素对肝脏疾病的防治作用及其机制

王慧丽 秦文昊 杨档档 宁雅倩 林杉 代崧霖 胡冰

引用本文:
Citation:

黄连素对肝脏疾病的防治作用及其机制

DOI: 10.12449/JCH241130
基金项目: 

国家自然科学基金 (82003005)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:王慧丽、秦文昊、胡冰负责课题设计,资料分析,撰写论文;王慧丽、秦文昊、杨档档、宁雅倩参与收集数据,修改论文;王慧丽、林杉、代崧霖负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    胡冰, drhubing@aliyun.com (ORCID: 0000-0003-4167-9038)

Preventive and therapeutic effects of berberine on liver diseases and its mechanism

Research funding: 

National Natural Science Foundation of China (82003005)

More Information
  • 摘要: 黄连素是临床常用的清热解毒药,目前常规被用于治疗细菌性胃肠炎、腹泻等消化道疾病。但近期多项研究表明,黄连素可通过调控腺苷酸活化蛋白激酶、转化生长因子-β等蛋白通路及改变肠道菌群构成,对自身免疫性肝炎、病毒性肝炎、非酒精性脂肪性肝病及肝癌等疾病产生治疗作用,不仅为这些疾病的治疗提供新的药物选择,扩展了黄连素的潜在适应证范围,也为后续类似药物的研发提供了线索。本文旨在总结黄连素对各类肝脏疾病的治疗作用及其机制,为临床的有效应用提供参考。

     

  • 图  1  BBR对肝脏疾病作用靶点汇总

    Figure  1.  Summary of the targets of berberine on liver diseases

  • [1] HU CY, MO ZX. Research progress on pharmacological actions and mechanism of berberine[J]. China Ind Econ, 2017, 23( 20): 213- 219. DOI: 10.13422/j.cnki.syfjx.2017200213.

    胡诚毅, 莫志贤. 黄连素的药理作用及机制研究进展[J]. 中国实验方剂学杂志, 2017, 23( 20): 213- 219. DOI: 10.13422/j.cnki.syfjx.2017200213.
    [2] WONGBUTDEE J. Physiological effects of berberine[J]. Thai Pharm Health Sci J, 2008( 4): 78- 83.
    [3] YAO J, KONG WJ, JIANG JD. Learning from berberine: Treating chronic diseases through multiple targets[J]. Sci China Life Sci, 2015, 58( 9): 854- 859. DOI: 10.1007/s11427-013-4568-z.
    [4] SHEN QM. Physiological function of liver[J]. Liver Dr, 2022( 4): 35- 37.

    沈启明. 肝脏的生理功能[J]. 肝博士, 2022( 4): 35- 37.
    [5] ZHOU MT, DENG Y, LIU MC, et al. The pharmacological activity of berberine, a review for liver protection[J]. Eur J Pharmacol, 2021, 890: 173655. DOI: 10.1016/j.ejphar.2020.173655.
    [6] LAN SH, TANG QY, LI NN, et al. Mechanism of action of Xiaochaihu Decoction in the treatment of hepatitis B based on network pharmacology[J]. J Clin Hepatol, 2021, 37( 10): 2308- 2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010.

    蓝绍航, 唐秋媛, 李娜娜, 等. 基于网络药理学研究小柴胡汤治疗乙型肝炎的作用机制[J]. 临床肝胆病杂志, 2021, 37( 10): 2308- 2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010.
    [7] GUO WZ, KANG Z. Old drugs and new drugs are used to treat viral hepatitis[J]. Int Med Health Guid Issues, 2005, 11( 12): 87- 88. DOI: 10.3760/cma.j.issn.1007-1245.2005.12.049.

    郭文征, 康庄. 老药新用治疗病毒性肝炎[J]. 国际医药卫生导报, 2005, 11( 12): 87- 88. DOI: 10.3760/cma.j.issn.1007-1245.2005.12.049.
    [8] LI F, LI B, ZHU QY. Research progress on the epidemiological characteristics and diagnosis of hepatitis C in China[J]. Int J Virol, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.

    黎锋, 李博, 朱秋映. 中国丙肝流行特征与诊断研究进展[J]. 国际病毒学杂志, 2023, 30( 6): 509- 511. DOI: 10.3760/cma.j.issn.1673-4092.2023.06.014.
    [9] HUNG TC, JASSEY A, LIU CH, et al. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein[J]. Phytomedicine, 2019, 53: 62- 69. DOI: 10.1016/j.phymed.2018.09.025.
    [10] WANG YY, ZHOU L, LI YN, et al. The effects of berberine on concanavalin A-induced autoimmune hepatitis(AIH) in mice and the adenosine 5'-monophosphate(AMP)-activated protein kinase(AMPK) pathway[J]. Med Sci Monit, 2017, 23: 6150- 6161. DOI: 10.12659/msm.907377.
    [11] KOWDLEY KV, FORMAN L, EKSTEEN B, et al. A randomized, dose-finding, proof-of-concept study of berberine ursodeoxycholate in patients with primary sclerosing cholangitis[J]. Am J Gastroenterol, 2022, 117( 11): 1805- 1815. DOI: 10.14309/ajg.0000000000001956.
    [12] PHOGAT A, SINGH J, KUMAR V, et al. Berberine mitigates acetamiprid-induced hepatotoxicity and inflammation via regulating endogenous antioxidants and NF-κB/TNF-α signaling in rats[J]. Environ Sci Pollut Res Int, 2023, 30( 37): 87412- 87423. DOI: 10.1007/s11356-023-28279-1.
    [13] MAHMOUD AM, HOZAYEN WG, RAMADAN SM. Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARγ, and suppressing oxidative stress and apoptosis in rats[J]. Biomed Pharmacother, 2017, 94: 280- 291. DOI: 10.1016/j.biopha.2017.07.101.
    [14] KOPERSKA A, WESOŁEK A, MOSZAK M, et al. Berberine in non-alcoholic fatty liver disease-a review[J]. Nutrients, 2022, 14( 17): 3459. DOI: 10.3390/nu14173459.
    [15] WANG CE, XU WT, GONG J, et al. Research progress in the treatment of nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [16] ZHU XP, BIAN H, WANG L, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway[J]. Free Radic Biol Med, 2019, 141: 192- 204. DOI: 10.1016/j.freeradbiomed.2019.06.019.
    [17] WANG P, LI RK, LI YQ, et al. Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice[J]. Gastroenterol Rep, 2023, 11: goad032. DOI: 10.1093/gastro/goad032.
    [18] SUN YX, XIA MF, YAN HM, et al. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21[J]. Br J Pharmacol, 2018, 175( 2): 374- 387. DOI: 10.1111/bph.14079.
    [19] ZHU L, XU JJ, LI HD, et al. Berberine ameliorates abnormal lipid metabolism via the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway in alcohol-related liver disease[J]. Lab Invest, 2023, 103( 4): 100041. DOI: 10.1016/j.labinv.2022.100041.
    [20] CHEN Y, LI Q, ZHAO SW, et al. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis[J]. Biochem Pharmacol, 2023, 218: 115928. DOI: 10.1016/j.bcp.2023.115928.
    [21] KHATER SI, ALMANAA TN, FATTAH DMA, et al. Liposome-encapsulated berberine alleviates liver injury in type 2 diabetes via promoting AMPK/mTOR-mediated autophagy and reducing ER stress: Morphometric and immunohistochemical scoring[J]. Antioxidants, 2023, 12( 6): 1220. DOI: 10.3390/antiox12061220.
    [22] CAI YJ, YANG QN, YU YQ, et al. Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: A review[J]. Front Pharmacol, 2023, 14: 1283784. DOI: 10.3389/fphar.2023.1283784.
    [23] YUAN XL, WANG J, TANG XY, et al. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles[J]. J Transl Med, 2015, 13: 24. DOI: 10.1186/s12967-015-0383-6.
    [24] DAI L, LU S, SHEN TB, et al. Methyltransferase SETD2 mediates hepatoprotection of berberine against steatosis[J]. Ann Transl Med, 2022, 10( 10): 552. DOI: 10.21037/atm-22-1753.
    [25] YANG FJ, GAO RM, LUO XX, et al. Berberine influences multiple diseases by modifying gut microbiota[J]. Front Nutr, 2023, 10: 1187718. DOI: 10.3389/fnut.2023.1187718.
    [26] ZHANG YY, YAN JJ, ZHANG P, et al. Berberine maintains gut microbiota homeostasis and ameliorates liver inflammation in experimental non-alcoholic fatty liver disease[J]. Chin J Gastroenterol, 2018, 23( 4): 209- 215. DOI: 10.3969/j.issn.1008-7125.2018.04.004.

    张园园, 严君君, 张培, 等. 黄连素调节肠道菌群减轻非酒精性脂肪性肝病肝脏炎症的实验研究[J]. 胃肠病学, 2018, 23( 4): 209- 215. DOI: 10.3969/j.issn.1008-7125.2018.04.004.
    [27] GUO HH, SHEN HR, WANG LL, et al. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases[J]. Biomed Pharmacother, 2023, 163: 114754. DOI: 10.1016/j.biopha.2023.114754.
    [28] WANG C, YANG YT, CHEN JY, et al. Berberine protects against high-energy and low-protein diet-induced hepatic steatosis: Modulation of gut microbiota and bile acid metabolism in laying hens[J]. Int J Mol Sci, 2023, 24( 24): 17304. DOI: 10.3390/ijms242417304.
    [29] YI JZ, WU SY, TAN SW, et al. Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis[J]. Cell Death Discov, 2021, 7( 1): 374. DOI: 10.1038/s41420-021-00768-7.
    [30] LI J, PAN Y, KAN MJ, et al. Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase[J]. Life Sci, 2014, 98( 1): 24- 30. DOI: 10.1016/j.lfs.2013.12.211.
    [31] LIU XZ, WANG LF, TAN SW, et al. Therapeutic effects of berberine on liver fibrosis are associated with lipid metabolism and intestinal flora[J]. Front Pharmacol, 2022, 13: 814871. DOI: 10.3389/fphar.2022.814871.
    [32] XIE ZP, ZHOU Y, LIN M, et al. Binding of berberine to PEBP1 synergizes with sorafenib to induce the ferroptosis of hepatic stellate cells[J]. Amino Acids, 2023, 55( 12): 1867- 1878. DOI: 10.1007/s00726-023-03345-7.
    [33] DOU Q, LI Y, WANG YY, et al. Effect of berberine on protecting liver function and inhibiting inflammation in cirrhotic rats[j]. J Guangzhou Univ Tradit Chin Med, 2021, 38( 12): 2708- 2715. DOI: 10.13359/j.cnki.gzxbtcm.2021.12.027.

    窦芊, 李赢, 王园园, 等. 小檗碱对肝硬化大鼠肝功能的保护及炎症抑制作用[J]. 广州中医药大学学报, 2021, 38( 12): 2708- 2715. DOI: 10.13359/j.cnki.gzxbtcm.2021.12.027.
    [34] WANG N, FENG YB, ZHU MF, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism[J]. J Cell Biochem, 2010, 111( 6): 1426- 1436. DOI: 10.1002/jcb.22869.
    [35] REN G, GUO JH, FENG CL, et al. Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model[J]. Mol Ther Oncolytics, 2022, 26: 372- 386. DOI: 10.1016/j.omto.2022.08.001.
    [36] GUO W, TAN HY, LI S, et al. Glutamic-pyruvic transaminase 1 facilitates alternative fuels for hepatocellular carcinoma growth-a small molecule inhibitor, berberine[J]. Cancers, 2020, 12( 7): 1854. DOI: 10.3390/cancers12071854.
    [37] ZHENG HL. Inhibitory effect of berberine on hepatocellular carcinoma metastasis and its mechanism by suppressing the‘phoenix rising’pathway[D]. Changchun: Jilin University, 2016.

    郑慧琳. 黄连素对“凤凰涅槃”信号通路引起肝癌转移的抑制作用及机制探讨[D]. 长春: 吉林大学, 2016.
    [38] DU HY, GU JY, PENG Q, et al. Berberine suppresses EMT in liver and gastric carcinoma cells through combination with TGFβR regulating TGF-β/smad pathway[J]. Oxid Med Cell Longev, 2021, 2021: 2337818. DOI: 10.1155/2021/2337818.
    [39] SHOU JW, SHAW PC. Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J]. Phytomedicine, 2023, 115: 154842. DOI: 10.1016/j.phymed.2023.154842.
    [40] LIN YB, SHENG MW, WENG YQ, et al. Berberine protects against ischemia/reperfusion injury after orthotopic liver transplantation via activating Sirt1/FoxO3α induced autophagy[J]. Biochem Biophys Res Commun, 2017, 483( 2): 885- 891. DOI: 10.1016/j.bbrc.2017.01.028.
    [41] GENDY AM, ELNAGAR MR, ALLAM MM, et al. Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-κB signaling and autophagy[J]. Biomed Pharmacother, 2022, 145: 112122. DOI: 10.1016/j.biopha.2021.112122.
    [42] SHENG M, ZHOU Y, YU W, et al. Protective effect of Berberine pretreatment in hepatic ischemia/reperfusion injury of rat[J]. Transplant Proc, 2015, 47( 2): 275- 282. DOI: 10.1016/j.transproceed.2015.01.010.
  • 加载中
图(1)
计量
  • 文章访问数:  55
  • HTML全文浏览量:  21
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-02-23
  • 录用日期:  2024-05-10
  • 出版日期:  2024-11-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回